Carisma Therapeutics (CARM)’ Board of Directors has approved and the Company intends to proceed with the voluntary delisting of its common stock from The Nasdaq Stock Market and the deregistration of ...
PHILADELPHIA, April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback